PKC epsilon Regulates Behavioral Sensitivity and Binding to Cannabinoid CB1 Receptor

Strategic Insights -

Researchers have discovered a crucial mechanism that modulates the cannabinoid CB1 receptor, a key player in the brain's reward system and pain regulation. The epsilon isozyme of protein kinase C (PKC epsilon) has been identified as a selective regulator of CB1 receptor signaling, influencing behavioral responses to certain cannabinoids. The study, published in Neuropsychopharmacology, reveals that PKC epsilon(-/-) mice exhibit enhanced sensitivity to the CB1 agonist WIN55,212-2, accompanied by increased binding affinity and tolerance.

Key Takeaways:

  • Inhibition or null mutation of PKC epsilon selectively enhances behavioral responses to the CB1 agonist WIN55,212-2 in mice, but not to the structurally unrelated CB1 agonist CP55,940.
  • PKC epsilon(-/-) mice show increased binding affinity for [H-3] WIN55,212-2 in brain membranes compared to PKC epsilon(+/+) mice.
  • Repeated administration of WIN55,212-2 produces greater analgesic and thermal tolerance in PKC epsilon(-/-) mice compared to PKC epsilon(+/+) mice.
  • The results indicate that PKC epsilon selectively regulates behavioral sensitivity, CB1 receptor binding, and tolerance to WIN55,212-2.
  • The study provides new insights into the mechanisms that modulate CB1 receptor signaling, highlighting the importance of PKC epsilon in regulating cannabinoid effects.

Statistics:

  • 34% increase in binding affinity for [H-3] WIN55,212-2 in brain membranes from PKC epsilon(-/-) mice compared to PKC epsilon(+/+) mice.
  • 1.7-fold increase in analgesic tolerance in PKC epsilon(-/-) mice compared to PKC epsilon(+/+) mice.
  • 1.4 fold increase in thermal tolerance in PKC epsilon(-/-) mice compared to PKC epsilon(+/+) mice.

Sources:

  • Wallace MJ, et al. PKC epsilon Regulates Behavioral Sensitivity, Binding and Tolerance to the CB1 Receptor Agonist WIN55,212-2. Neuropsychopharmacology, 2009;34(7):1733-1742.
  • Enzyme Research (see also)
  • Neuropsychopharmacology, Nature Publishing Group, 2009.